Lessons from the Front Lines: Navigating the Operational Challenges of Next-Generation ADC Trials

As oncology innovation accelerates, the biological and toxicological complexity of next-generation ADCs is prompting sponsors to rethink traditional trial execution. By replacing transactional vendor relationships with collaborative partnerships and real-time digital monitoring, biopharma sponsors can build resilient protocols that safeguard patient safety and sustain trial momentum.

The clinical development of targeted antibody-drug conjugates (ADCs) is the most competitive and fast-moving frontier in oncology. However, groundbreaking science does not guarantee clinical success; the ultimate success of these therapies depends on well-executed clinical trials. Drawing on experience supporting more than 30 global ADC clinical projects involving over 9,200 patients across 2,080 sites, several operational themes have consistently emerged as influencing trial success. Because next-generation ADC development must simultaneously navigate unknown target behaviors, complex payload toxicities, and emerging resistance pathways, these programs are fluid, ongoing scientific endeavors that demand a new approach to trial execution.